Abstract
Background: At present, there is still no significant progress in the diagnosis and treatment of thyroidassociated ophthalmopathy. Objective: We explored the role of 99mTc-octreotide single photon emission computed tomography (SPECT) in determination of the clinical activity of thyroid-associated ophthalmopathy (TAO). Methods: A prospective study including 36 cases of TAO and 8 controls was conducted by intravenous injection of 99mTc-octreotide, followed by SPECT. The radioactive counting ratio was calculated for the orbital/occipital regions of interest (ROI), and the Spearman rank correlation between the average ratio and the corresponding clinical activity score (CAS) mean of ADHOC (Recommendation of the Ad Hoc Committee of The American Thyroid Association in 1992) was analyzed. A curve regression equation for the CAS to orbital/occipital radio counting ratio was determined to calculate the cutoff for TAO activity. Results: The Spearman rank correlation between orbital/occipital uptake ratio and CAS was calculated (coefficient r = 0.972, p Conclusion: 99mTc-octreotide SPECT can objectively and accurately measure TAO activity. An orbital/occipital uptake ratio >1.48 is the recommended cutoff to determine the active phase of TAO. This may guide clinical treatment of TAO. Keywords: Clinical activity, SPECT, thyroid-associated ophthalmopathy, 99mTc-octreotide
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
